Vaccination with priming and expansion of tumour reacting T cells is an important therapeutic option to be used in combination with novel checkpoint inhibitors to increase the specificity of the T cell infiltrate and the efficacy of the treatment. In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide. Patients were subjected to 6 doses of vaccine every two weeks and a recall dose after 3 months. ECOG grade 2 toxicity was observed at the injection site. Eight out of 14 patients showed specific CD8+ T cells to at least one antigen. None of 4 patients vaccinated for compassionate use showed a CD8 activation. An OC patient who suffered from a lymph nodal recurrence, showed specific anti-ErbB2 CD8+ T cells in the bulky aortic lymph nodes suggesting homingof the activated T cells. Results confirm that peptide vaccination strategy is feasible, safe and well tolerated. In particular OC patients appear to show a higher response rate compared to BC patients. Vaccination generates a long-lasting immune response, which is strongly enhanced by recall administrations. The clinical outcome of patients enrolled in the trial appears favourable, having registered no deceased patients with a minimum follow-up of 8 years. These promising data, in line with the results of similar studies, the high compliance of patients observed and the favourable toxicity profile, support future trials of peptide vaccination in clinically disease-free patients who have completed standard treatments.

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial / Antonilli, M; RAHIMI KOSHKAKI, Hassan; Visconti, Valeria; Napoletano, Chiara; Ruscito, Ilary; Zizzari, ILARIA GRAZIA; Caponnetto, Salvatore; Barchiesi, Giacomo; Iadarola, R; Pierelli, Luca; Rughetti, Aurelia; Bellati, Filippo; BENEDETTI PANICI, Pierluigi; Nuti, Marianna. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - STAMPA. - 48:4(2016), pp. 1369-1378. [10.3892/ijo.2016.3386]

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial

RAHIMI KOSHKAKI, HASSAN
Secondo
;
VISCONTI, Valeria;NAPOLETANO, Chiara;RUSCITO, ILARY;ZIZZARI, ILARIA GRAZIA;CAPONNETTO, SALVATORE;BARCHIESI, GIACOMO;PIERELLI, LUCA;RUGHETTI, Aurelia;BELLATI, FILIPPO;BENEDETTI PANICI, PIERLUIGI
Penultimo
;
NUTI, Marianna
Ultimo
2016

Abstract

Vaccination with priming and expansion of tumour reacting T cells is an important therapeutic option to be used in combination with novel checkpoint inhibitors to increase the specificity of the T cell infiltrate and the efficacy of the treatment. In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide. Patients were subjected to 6 doses of vaccine every two weeks and a recall dose after 3 months. ECOG grade 2 toxicity was observed at the injection site. Eight out of 14 patients showed specific CD8+ T cells to at least one antigen. None of 4 patients vaccinated for compassionate use showed a CD8 activation. An OC patient who suffered from a lymph nodal recurrence, showed specific anti-ErbB2 CD8+ T cells in the bulky aortic lymph nodes suggesting homingof the activated T cells. Results confirm that peptide vaccination strategy is feasible, safe and well tolerated. In particular OC patients appear to show a higher response rate compared to BC patients. Vaccination generates a long-lasting immune response, which is strongly enhanced by recall administrations. The clinical outcome of patients enrolled in the trial appears favourable, having registered no deceased patients with a minimum follow-up of 8 years. These promising data, in line with the results of similar studies, the high compliance of patients observed and the favourable toxicity profile, support future trials of peptide vaccination in clinically disease-free patients who have completed standard treatments.
peptide-based vaccination; MUC1/ErbB2/CEA; ovarian cancer; breast cancer; immunotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial / Antonilli, M; RAHIMI KOSHKAKI, Hassan; Visconti, Valeria; Napoletano, Chiara; Ruscito, Ilary; Zizzari, ILARIA GRAZIA; Caponnetto, Salvatore; Barchiesi, Giacomo; Iadarola, R; Pierelli, Luca; Rughetti, Aurelia; Bellati, Filippo; BENEDETTI PANICI, Pierluigi; Nuti, Marianna. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - STAMPA. - 48:4(2016), pp. 1369-1378. [10.3892/ijo.2016.3386]
File allegati a questo prodotto
File Dimensione Formato  
Antonilli_Triple-peptide-vaccination_2016.pdf

accesso aperto

Note: https://www.spandidos-publications.com/ijo/48/4/1369
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 591.94 kB
Formato Adobe PDF
591.94 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/849256
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 21
social impact